Since 1878, we have been committed to developing new treatments to improve patients' lives worldwide. We are helping to address global health challenges such as antimicrobial resistance and COVID-19. Since the 1950s, we have discovered and introduced several novel antibiotics, as well as innovative medications for HIV and influenza. Today, we are developing an investigational oral antiviral for COVID-19 and advancing clinical programs in Fragile X syndrome, acute ischemic stroke as well metabolic disorders and oncology. Our team is driven to impact patient lives. Our partnerships with industry, government agencies, biotech companies and academia help to advance science with the urgency that today's health challenges demand. Through a combination of in-house discovery and strategic partnerships, we continue to deliver firsts for patients in the U.S. and worldwide.
View Top Employees from Shionogi Inc.Website | http://www.shionogi.com |
Revenue | $33.34 billion |
Employees | 504 (504 on RocketReach) |
Founded | 2001 |
Phone | (973) 966-6900 |
Industry | Pharmaceutical Manufacturing, Manufacturing General, Manufacturing |
Web Rank | 7 Million |
Keywords | Pharmaceutical Products, Infectious Disease, Pain Management, Adhd |
Competitors | Amneal Pharmaceuticals, Emcure Pharmaceuticals Limited, HIPRA, Hikma Pharma Egypt, Lannett Company, Inc. |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular Shionogi Inc. employee's phone or email?
The Shionogi Inc. annual revenue was $33.34 billion in 2024.
Simon Portsmouth is the Senior Vice President of Shionogi Inc..
504 people are employed at Shionogi Inc..
The NAICS codes for Shionogi Inc. are [3254, 32541, 32, 325].
The SIC codes for Shionogi Inc. are [28, 283].